Table 1

KEGG Pathway Enrichment

ENV HHP

ENV HHE

NEF HHP

NEF HHE

TAT HHP

TAT HHE


AML

1.97E-05

2.68E-05

2.07E-05

8.55E-05

2.66E-08

3.08E-04

Adherens junction

2.15E-09

NA

8.21E-11

NA

6.74E-06

NA

Apoptosis

4.58E-04

1.43E-13

5.18E-04

6.54E-04

3.91E-03

3.88E-13

B cell receptor signaling pathway

4.86E-06

8.73E-10

2.88E-04

2.90E-04

1.25E-09

5.57E-06

Cell cycle

NA

NA

NA

NA

2.88E-04

1.90E-01

CML

7.21E-05

2.23E-05

1.17E-06

2.46E-05

1.01E-09

7.53E-07

Colorectal cancer

1.07E-05

3.18E-04

4.68E-08

3.31E-03

4.50E-04

1.42E-03

Endometrial cancer

6.03E-04

1.62E-02

1.66E-04

2.10E-03

5.03E-07

3.83E-04

Epithelial cell signaling in H. pylori infection

2.29E-04

3.84E-06

2.07E-06

2.83E-05

NA

NA

ErbB signaling

2.27E-10

5.70E-04

1.70E-12

9.22E-04

1.53E-12

1.66E-05

Fc epsilon RI signaling pathway

8.43E-04

6.23E-21

2.14E-05

2.20E-07

9.62E-05

1.52E-04

Focal adhesion

2.82E-06

2.30E-03

2.31E-07

6.90E-02

5.28E-08

3.36E-09

Gap junction

1.90E-04

1.26E-04

NA

NA

1.12E-04

7.18E-10

Glioma

1.50E-04

1.24E-05

4.99E-06

6.02E-03

1.56E-07

6.79E-11

Insulin signaling

1.53E-07

8.84E-02

1.73E-04

3.50E-01

2.91E-07

7.35E-02

Jak-STAT signaling

4.08E-08

2.15E-04

4.09E-09

1.28E-01

2.32E-17

4.91E-03

Leukocyte transendothelial migration

1.94E-07

2.21E-08

1.17E-08

6.36E-01

3.28E-05

1.45E-01

Long-term potentiation

6.79E-05

2.20E-02

NA

NA

9.04E-03

2.38E-10

MAPK signaling

5.19E-08

6.32E-04

1.58E-09

3.27E-03

1.18E-03

5.15E-01

NK cell mediated cytotoxicity

NA

NA

NA

NA

9.50E-06

5.31E-15

Non-small cell lung cancer

4.28E-05

1.25E-04

1.26E-05

1.67E-03

7.55E-06

1.45E-06

Pancreatic cancer

1.26E-04

5.54E-07

1.10E-05

2.50E-06

1.03E-05

8.15E-08

Pathogenic E. coli infection – EHEC

3.77E-03

1.00E+00

2.94E-03

NA

9.74E-03

3.25E-01

Phosphatidylinositol signaling system

1.36E-03

1.72E-04

2.37E-03

NA

2.19E-05

9.74E-06

Prostate cancer

1.90E-04

1.26E-04

6.26E-06

6.56E-05

5.46E-09

1.11E-07

Regulation of actin cytoskeleton

4.30E-03

6.02E-01

1.73E-03

8.79E-01

2.66E-03

7.65E-01

Small cell lung cancer

1.94E-03

3.71E-10

8.42E-05

4.25E-02

1.12E-04

4.09E-14

T cell receptor signaling pathway

NA

NA

NA

NA

1.56E-06

1.35E-11

Tight junction

1.24E-03

1.00E+00

5.29E-04

NA

NA

NA

Toll-like receptor signaling pathway

5.16E-03

2.04E-14

5.37E-05

2.04E-14

NA

NA

Type II diabetes mellitus

NA

NA

NA

NA

3.47E-03

5.95E-01

VEGF signaling

3.23E-03

4.89E-15

6.79E-03

8.82E-03

1.88E-05

4.07E-12


KEGG Pathways enriched (p-value < 0.01, see Methods) in HHP for HIV-1 ENV, NEF, and TAT. HHE enrichment is also indicated.

Evans et al. BMC Medical Genomics 2009 2:27   doi:10.1186/1755-8794-2-27

Open Data